Sofinno­va Telethon Fund backs Nal­dini's gene ther­a­py biotech; ORIC prices $75M IPO

→ The Sofinno­va Telethon Fund has found a new gene ther­a­py up­start to back. The fund se­lect­ed Gene­spire for its port­fo­lio, tap­ping a biotech in­spired by the work of Lui­gi Nal­di­ni, a leg­endary sci­en­tist in the field. The biotech was found­ed last month by Nal­di­ni, pro­fes­sor Alessio Can­tore, The Telethon Foun­da­tion and San Raf­faele Hos­pi­tal. It is a spin-off of SR-Tiget. Graziano Seghezzi, man­ag­ing part­ner of Paris-based Sofinno­va Part­ners, plays a big role in al­lo­cat­ing the funds. This is Sofinno­va’s third in­vest­ment in 6 months, to­tal­ing €25 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER